Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 8:15AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2014.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
PR Newswire - Mon May 05, 6:00PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Repros Therapeutics, Inc. ("Repros" or the "Company"
FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel
GlobeNewswire - Wed Apr 30, 3:12PM CDT
-- Co-primary endpoints of better maintenance of normal sperm concentration and smaller decline in sperm concentration, both compared to topical gel
Repros Completes Enrollment for Androxal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:15PM CDT
Repros Therapeutics announced it has completed enrollment for one of the two head-to-head studies on its secondary hypogonadism candidate, Androxal.
Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel
GlobeNewswire - Mon Apr 14, 9:34AM CDT
-- Company expects topline results by October 2014
Repros Provides Proellex Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:10PM CDT
Repros Therapeutics announced that it has received guidance from the FDA related to Proellex.
Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis
GlobeNewswire - Mon Mar 17, 8:20AM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today reported it has received guidance from the FDA indicating that Repros may proceed to conduct Phase 1 and 2 studies of oral Proellex under two separate INDs for endometriosis and uterine fibroids, while remaining on partial clinical hold. The FDA guidance provides that the highest allowed dose will be 12 mg daily. Repros is currently conducting a Phase 2 study for the use of Proellex in severe endometriosis and plans to submit a Phase 2 protocol for the treatment of symptomatic fibroids.
Narrower-than-Expected Q4 Loss at Repros - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:50AM CDT
Repros fourth quarter 2013 loss of 31 cents per share was narrower than the year-ago loss of 47 cents.
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Thu Mar 13, 8:15AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2013.
Bullish Two Hundred Day Moving Average Cross - RPRX
MarketNewsVideo.com - Tue Feb 18, 3:38PM CST
In trading on Tuesday, shares of Repros Therapeutics Inc crossed above their 200 day moving average of $19.54, changing hands as high as $19.87 per share. Repros Therapeutics Inc shares are currently trading up about 6% on the day.
Data on Repros' Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 5:26PM CST
Repros Therapeutics recently released additional results from its phase III study, ZA-300, on candidate Androxal.
Repros Therapeutics (RPRX) Jumps: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:46AM CST
Repros Therapeutics was a big mover last session, with shares rising over 6%.
Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism
GlobeNewswire - Mon Feb 10, 8:39AM CST
-- Greater Than 80% of Men Obtained T in the Normal Range
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Repros Shares Soar After FDA Meeting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:27AM CST
Share price of Repros surged 15.8% after its meeting with the FDA on Androxal
Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Repros Therapeutics, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 06, 2:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repros Therapeutics , a clinical-stage...
Repros Therapeutics rises on Androxal update
AP - Thu Feb 06, 10:35AM CST
NEW YORK (AP) — Shares of Repros Therapeutics jumped Thursday after the company said it doesn't think it will have to run additional safety studies of its testosterone drug Androxal.